LPLP
PDLI

Lansdowne Partners Limited Partnership’s PDL BioPharma, Inc. PDLI Stock Holding History

Lansdowne Partners Limited Partnership’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-10,080
Closed -$85K – 63
2013
Q4 		$85K Hold
10,080
– – ﹤0.01% 44
2013
Q3 		$80K Hold
10,080
– – ﹤0.01% 36
2013
Q2 		$78K Buy
+10,080
New +$78.6K ﹤0.01% 42

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lansdowne Partners Limited Partnership's PDLI Position: Q1 2014 in Review

Lansdowne Partners Limited Partnership sold out of PDL BioPharma, Inc. (PDLI) in Q1 2014, closing a stake of 10,080 shares — an estimated $85K sold.

Lansdowne Partners Limited Partnership first reported a position in PDLI in Q2 2013 and held it in 3 quarters. The position peaked at $85K in Q4 2013. 233 funds tracked by Wall St. Rank hold PDLI as of Q1 2014.

  • Lansdowne Partners Limited Partnership reported no remaining PDL BioPharma, Inc. position as of Q1 2014 after selling out during the quarter.
  • Lansdowne Partners Limited Partnership sold 10,080 PDL BioPharma, Inc. shares in Q1 2014, an estimated $85K.
  • Lansdowne Partners Limited Partnership first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 3 quarters.
  • Lansdowne Partners Limited Partnership's PDL BioPharma, Inc. position peaked at $85K in Q4 2013.
  • 233 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2014.

Based on Lansdowne Partners Limited Partnership's 13F filing for Q1 2014, filed 14 May 2014.